Sellas Life Sciences to host KOL webinar on GPS AML program

SELLAS Life Sciences Group will host a virtual key opinion leader event to discuss the current treatment landscape for patients suffering from acute myeloid leukemia and the potential for galinpepimut-S as a treatment solution. The webinar event will feature Omer Jamy, MD who is principal investigator of the Phase 3 REGAL study at the University of Alabama at Birmingham, one of the highest enrolling REGAL sites. He is currently Assistant Professor of Medicine at UAB in the Division of Hematology and Oncology and Associate Scientist, Experimental Therapeutics at the O’Neal Comprehensive Cancer Center. Dr. Jamy is principal investigator on several clinical trials in addition to REGAL, focusing on AML, chronic myelogenous leukemia, and allogeneic stem cell transplantation. Dr. Jamy completed his internal medicine residency at the University of Tennessee in Memphis followed by fellowship training at UAB in hematology/oncology, bone marrow transplantation and cellular therapy. The SELLAS management team will provide a corporate update on GPS, their lead pipeline candidate, which is currently being evaluated in a Phase 3 registrational clinical trial in AML patients who have achieved complete remission following second-line salvage therapy. GPS targets malignancies and tumors characterized by an overexpression of the WT1 antigen, one of the most widely expressed cancer antigens in multiple malignancies.